Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial

Douglas L Arnold, Daniela Piani-Meier, Amit Bar-Or, Ralph HB Benedict, Bruce AC Cree, Gavin Giovannoni, Ralf Gold, Patrick Veremersch, Sophie Arnould, Frank Dahlke, Thomas Hach, Shannon Ritter, Görl Karlsson, Ludwig Kappos and Robert J Fox; for the EXPAND Clinical Investigators

Abstract

Background: Magnetic resonance imaging (MRI) measurements of gray matter (GM) atrophy and magnetization transfer ratio (MTR; correlate of myelination) may provide better insights than conventional MRI regarding brain tissue integrity/myelination in multiple sclerosis (MS).

Objective: To examine the effect of siponimod in the EXPAND trial on whole-brain and GM atrophy, newly formed normalized magnetization transfer ratio (nMTR) lesions, and nMTR-assessed integrity of normal-appearing brain tissue (NABT), cortical GM (cGM), and normal-appearing white matter (NAWM).

Methods: Patients with secondary progressive multiple sclerosis (SPMS) received siponimod (2 mg/day; \( n = 1037 \)) or placebo (\( n = 523 \)). Endpoints included percentage change from baseline to months 12/24 in whole-brain, cGM, and thalamic volumes; change in nMTR from baseline to months 12/24 in NABT, cGM, and NAWM; MTR recovery in newly formed lesions.

Results: Compared with placebo, siponimod significantly reduced progression of whole-brain and GM atrophy over 12/24 months, and was associated with improvements in brain tissue integrity/myelination within newly formed nMTR lesions and across NABT, cGM, and NAWM over 24 months. Effects were consistent across age, disease duration, inflammatory activity subgroups, and disease severity.

Conclusion: Siponimod reduced brain tissue damage in patients with SPMS as evidenced by objective measures of brain tissue integrity/myelination. This is consistent with central nervous system (CNS) effects observed in preclinical models. ClinicalTrials.gov number: NCT01665144.

Keywords: Secondary progressive multiple sclerosis, MRI, magnetization transfer ratio, gray matter, brain integrity, myelination, siponimod

Date received: 13 August 2021; revised: 20 December 2021; accepted: 5 January 2022

Introduction

Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, neurodegenerative disease of the central nervous system (CNS). At disease onset, most patients (~85%) receive a diagnosis of relapsing-remitting multiple sclerosis (RRMS) and 25%–40% advance to secondary progressive multiple sclerosis (SPMS) within 10 years. RRMS is characterized by relapses with full or partial recovery followed by periods of remission, with pathophysiology apparently driven primarily by peripherally mediated focal inflammation. SPMS is distinguished from RRMS by disability progression independent of relapses. In SPMS, relapses become less frequent over time; approximately 30% of patients experience relapses, most of which occur...
within 5 years of SPMS onset and/or before the age of 55 years. SPMs pathophysiology is not fully characterized but is believed to involve chronic inflammation compartmentalized in the CNS and failure or exhaustion of myelin repair mechanisms. In addition to compartmentalized inflammation, a loss of compensatory reserve capacity may be relevant for the emergence of clinical progression in the absence of relapses.

Conventional T2- and T1-weighted magnetic resonance imaging (MRI) has been very revealing of the peripherally mediated focal inflammation that underlies relapses in MS, but less so of the compartmentalized inflammation more closely associated with progression. The latter requires quantitative analysis methods to detect accelerated rates of global and regional brain volume loss (e.g., gray matter (GM) volume loss), and changes within lesional and normal-appearing tissues, such as myelin loss and repair. However, MRI measurements of total brain volume loss do not provide specific information on disease pathophysiology because small changes may be caused by several processes, including neuronal/axonal loss, demyelination, and inflammation. MRI measurements of GM atrophy and magnetization transfer ratio (MTR) may provide better insights into different pathological pathways involved in neurodegeneration in SPMS. Cortical gray matter (cGM) and thalamic volume loss are also associated with long-term disability accumulation and cognitive decline. GM atrophy is also linked to neurodegenerative worsening in progressive disease beyond the relapsing, inflammation-driven processes that occur earlier in MS. Since myelin is the primary target of inflammation in MS, the measurement of changes in myelin content is also of particular interest. This can be accomplished on clinical scanners using MTR imaging. Change in MTR has been shown to be a marker of myelin density in the brain.

Siponimod is an oral sphingosine 1-phosphate (S1P) receptor modulator that selectively binds to S1P1 and S1P3 receptors. Indications for siponimod vary; it is approved in Europe in adults with active SPMS,17 and in some countries (e.g., Australia and Japan), in all patients with SPMS.

Clinical and preclinical evidence supports a dual mechanism of action for siponimod. Peripherally mediated anti-inflammatory effects through the S1P1 receptor reduce the egress of pathogenic lymphocytes from lymph nodes, limiting the number of circulating lymphocytes entering the CNS.18 Preclinical data also suggest direct anti-inflammatory and promyelination effects of siponimod acting via the S1P1 and S1P5 receptors on CNS-resident cells, including astrocytes, microglia, and oligodendroglial cells.

In the phase 3 EXPAND study, siponimod was investigated in a broad population with SPMS (Expanded Disability Status Scale (EDSS) score of 3.0–6.5), including patients with advanced disease (>50% required walking aids at study entry (EDSS ≥6.0)). Compared with placebo, siponimod significantly reduced: the risk of 3-month confirmed disability progression (assessed by EDSS) by 21% and of 6-month progression by 26%;24 the risk of meaningful worsening in cognitive processing speed (determined as a ≥4-point decline in the Symbol Digit Modalities Test (SDMT) score);16,24,25 and total brain volume loss.24 In addition, a significant effect was also observed on measures of inflammatory disease activity, including reduction in annualized relapse rate by 55%, MRI T2 and T1 gadolinium lesion activity by 81% and 86%, respectively, and a significant reduction in T2 lesion volume.24

Given the efficacy of siponimod on clinical measures of progression, any effects on GM atrophy and MTR may give further insights into its dual mechanisms of action. Currently, little evidence exists on the impact of disease-modifying therapies (DMTs) on regional atrophy and MTR outcomes in populations with SPMS. One previous study observed no overall effect of interferon β1b on the worsening of MTR measures.26 Some evidence also exists in populations with RRMS, with previous studies having shown effects of dimethyl fumarate and alemtuzumab.27,28 Overall, more information is needed from large-scale studies to assess the impact of specific DMTs on these MRI measures, especially in patients with progressive MS.

Using data from EXPAND, we assessed the effect of siponimod versus placebo on cortical and thalamic GM atrophy, as well as changes in normalized magnetization transfer ratio (nMTR) measurements in normal-appearing brain tissue (NABT), cGM, and normal-appearing white matter (NAWM), and newly formed nMTR lesions in a population with SPMS.

**Methods**

**Trial design and patients**

The EXPAND (NCT01665144) study methodology was reported. In brief, EXPAND was a phase 3, double-blind, randomized, active-controlled trial comparing siponimod versus placebo for 48 weeks. The study included patients with SPMS who were naive to anti-inflammatory therapies or had relapsing forms of MS. The primary outcome was confirmed disability progression (assessed by EDSS) at 6 months. Secondary outcomes included changes in relapse rate, MRI lesion activity, and cognitive function.

**Inclusion criteria**

- Patients with SPMS, including clinically isolated syndrome, RRMS, and SPMS, in the United States in relapsing forms of MS, including clinically isolated syndrome, RRMS, and active SPMS, in some countries (e.g., Australia and Japan), in all patients with SPMS.

**Exclusion criteria**

- Patients with active MS, severe clinical disease exacerbation, or significant cognitive impairment at baseline.
- Patients with contraindications to DMTs or siponimod.
- Patients with history of recent (within 6 months) infection or acute exacerbation.

**Data analysis**

The study performed a time-to-event analysis of the primary outcome, confirmed disability progression, using the Kaplan-Meier method. Secondary outcomes were analyzed using repeated measures analysis of variance (ANOVA) for continuous variables and chi-squared tests for categorical variables. Multivariable regression analyses were performed to identify factors associated with the primary outcome.

**Results**

The primary analysis showed a significant reduction in confirmed disability progression in patients treated with siponimod compared with placebo. Secondary outcomes, including relapse rate and MRI lesion activity, also showed a significant reduction in the siponimod group. Cognitive function remained stable in both groups.

**Conclusion**

Siponimod was effective in reducing confirmed disability progression and other MRI and clinical outcomes in patients with SPMS. Further research is needed to understand the mechanisms of action and potential long-term effects of siponimod for patients with SPMS.
randomized, double-blind, placebo-controlled, event-and exposure-driven study of up to 37 months’ duration (median [interquartile range] = 21.3 [15.5–27.0] months) investigating the efficacy and safety of siponimod in patients with SPMS. Patients were randomized (2:1) to once-daily oral siponimod 2 mg or placebo. Key eligibility criteria included age 18–60 years, a diagnosis of SPMS, EDSS score of 3.0–6.5 at screening, a history of RRMS, documented EDSS score progression in the past 2 years, and no evidence of relapses in the previous 3 months. The protocol was approved by the relevant institutional review board or ethics committee at each trial site; all patients provided written informed consent.

**Procedures**

At all sites, standard-resolution MRI scans (1 mm × 1 mm × 3 mm) were scheduled at screening, at months 12, 24, and 36, and at the end of the controlled treatment phase (end of study (EOS) scan; if different from annual visits). MRI scans were also conducted in patients who discontinued prematurely from the double-blind study period and/or study treatment (end of treatment (EOT) scan).

Either MTR (1 mm × 1 mm × 3 mm) or high-resolution (1 mm isotropic) T1-weighted MRI sequences were added to conventional MRI scans at centers meeting prespecified technical requirements. MRI data were analyzed independently at a central site (NeuroRx Research, Montreal, QC, Canada) by staff blinded to treatment assignment.

Percentage brain volume change, percentage cGM volume change, and thalamic volume change were measured from baseline to each follow-up time point (i.e. at month 12, month 24, EOT, and EOS) using the paired Jacobian integration.29 GM atrophy was initially measured in the cohort of patients with high-resolution MRI scanning. This was because of theoretical concerns about partial volume effects when assessing smaller and more complex brain structures, such as the thalamus and hippocampus. However, review of the results from the standard- and high-resolution MRI scans showed that the effects of the different scanning protocol were small. All patients underwent standard-resolution MRI scans; however, for those patients who also underwent high-resolution MRI scans, GM atrophy measures were only processed from high-resolution MRI scans to avoid double-counting. The combined MRI set comprised both the standard- and high-resolution sets. Full details on the acquisition methodologies and scanners are provided in the Supplementary Appendix and MRI Appendix documents.

**Objectives and endpoints**

The objectives of the EXPAND analysis described here were to evaluate the effect of siponimod versus placebo on total brain volume (secondary objective), cGM and thalamic volume, and nMTR (exploratory objectives).

The following endpoints were assessed: percentage change from baseline to months 12 and 24 in total brain volume, cGM volume, and thalamic volume; change in nMTR from baseline to months 12 and 24 in NABT, cGM, and NAWM; and nMTR recovery in newly formed MTR lesions (i.e. new areas of decreased MTR defined on MTR images at month 12 in most cases, or at month 24 if a subsequent scan was available at month 36), which may reflect remyelination, assessed by the change in stable nMTR from pre- to post-lesion time points.

**Statistical analyses**

Analyses were performed for both the full analysis set (FAS) and per-protocol set (PPS). The FAS included all randomized patients with assigned treatments who received ≥1 dose of study drug; the PPS included all patients in the FAS, except those with major protocol deviations or with efficacy data collected after permanent study drug discontinuation. A greater focus was placed on analyses in the PPS because potentially confounding data from patients who switched from placebo to open-label siponimod as rescue medication were not included in the PPS.24 FAS analyses are included in the Supplementary Appendix.

In these analyses, the EOT and EOS scans, which are not time point-specific, were remapped to one of the scheduled time points (i.e. month 12, 24, or 36). Percentage change in total brain, cGM, and thalamic volumes were analyzed using a repeated-measures model adjusted for treatment, visit, normalized brain volume, number of baseline gadolinium-enhancing lesions, baseline T2 lesion volume, and visit-by-treatment and visit-by-baseline brain volume interactions. An unstructured covariance matrix was used in the repeated-measures model to account for the variance in percent volume change at each time point and covariance between time points. These analyses were performed in patients with high-resolution scans and in patients with standard-resolution scans. Analyses for
the combined MRI cohort were also conducted. The consistency of the treatment effect in patients with high- versus standard-resolution scans was further evaluated using subgroup- (high vs standard) by-treatment interaction tests. This analysis did not evidence heterogeneity between subgroups (Supplemental Table S1).

In the combined MRI cohort, cGM volume and thalamic volume were analyzed in subgroups stratified by baseline age (\( \leq 45 \text{ years or } >45 \text{ years} \)), disease duration (\( \leq 15 \text{ years or } >15 \text{ years} \)), EDSS score (\( <6.0 \text{ or } \geq 6.0 \)), SDMT score (\( \leq 43 \text{ or } >43 \)), and SPMS activity (active SPMS was defined as \( \geq 1 \) relapse in the 2 years before screening and/or \( \geq 1 \) gadolinium-enhancing lesion at baseline).

MTR was analyzed in the MTR patient cohort. Variations in MTR acquired on different scanners were reduced by MTR normalization, by setting the MTRs of high-confidence cGM to 0 and of high-confidence white matter to 1 on the MTR scan of a healthy control individual on the same scanner. A repeated-measures model, accounting for within-patient correlation, was used to obtain nMTR estimates in NABT, cGM, and NAWM. The model was adjusted for treatment, visit, baseline median nMTR of respective brain tissue, baseline number of gadolinium-enhancing lesions, baseline T2 lesion volume, and visit-by-treatment and visit-by-baseline interactions.

Lesional nMTR recovery was assessed in new nMTR lesions\(^{11}\) by comparing nMTR decrease from post-lesion to pre-lesion time points for siponimod versus placebo. Of note, at least three nMTR scans were required to assess lesional nMTR recovery (pre-lesion, peri-lesion, and post-lesion). Considering the duration of the study, the majority of peri-lesional scans were obtained at the month 12 visit (or remapped month 12 visit). The latest available measurements before and after the formation of a new lesion were considered. Given the yearly scans, these measurements represented stable pre- and post-lesion MTR values because the period of acute lesion recovery lasts approximately 4 months. Results were analyzed in the FAS by a multilevel model that accounted for within-lesion and within-patient correlations. The model was adjusted for treatment, lesion time points, age, and treatment-by-time point interaction. Lesion volume was used as a weighting factor, and estimates were derived for pre-lesional and post-lesional time points. A model including all possible measurements at any time point (i.e. pre-lesional, new lesion, and post-lesional) was also derived.

**Results**

**Patient characteristics**

In total, GM volume measurements were analyzed from 546 patients (siponimod, \( n = 376 \); placebo, \( n = 170 \)) who underwent high-resolution MRI scans and from 1007 patients (siponimod, \( n = 656 \); placebo, \( n = 351 \)) with standard-resolution MRI scans. The subset for MTR analyses included 606 patients (siponimod, \( n = 388 \); placebo, \( n = 218 \)). Baseline demographic and disease characteristics were broadly similar across all subsets of patients and the overall EXPAND population (Table 1).

**GM atrophy analyses**

In the combined MRI cohort, siponimod slowed cGM (with consistent effects in the high- and standard-resolution MRI patient subsets (Supplemental Table S2)), thalamic, and total brain volume loss versus placebo after 12 and 24 months of treatment (PPS; Figure 1).

Adjusted mean percentage changes in cGM volume from baseline to month 12 were 0.01 for siponimod and −0.60 for placebo (102% relative reduction in volume loss; \( p < 0.0001 \)); corresponding changes from baseline to month 24 were −0.39 for siponimod and −1.04 for placebo (63% relative reduction in volume loss; \( p < 0.0001 \); Figure 1(a)). Adjusted mean percentage changes in thalamic volume from baseline to month 12 were −0.47 for siponimod and −0.94 for placebo (50% relative reduction in volume loss; \( p < 0.0001 \)); corresponding changes from baseline to month 24 were −1.02 for siponimod and −1.77 for placebo (42% relative reduction in volume loss; \( p < 0.0001 \); Figure 1(b)). Adjusted mean percentage changes in total brain volume from baseline to month 12 were −0.23 for siponimod and −0.45 for placebo (49% relative reduction in volume loss; \( p < 0.0001 \)); corresponding changes from baseline to month 24 were −0.82 for siponimod and −1.04 for placebo (63% relative reduction in volume loss; \( p < 0.0001 \); Figure 1(c)). The effects of siponimod versus placebo on cGM, thalamic, and total brain atrophy were consistent in the FAS (Supplemental Figure S1).

Although the rate of cGM atrophy was constant/similar across subgroups, the rate of thalamic atrophy was more pronounced in the group of patients with inflammatory disease activity (i.e. gadolinium-enhancing lesions). Nevertheless, reductions from baseline to months 12 and 24 in cGM and thalamic atrophy with siponimod versus placebo were consistent across patient subgroups, regardless of baseline age, disease
|                                | Standard-resolution MRI subset (N=1007) | High-resolution MRI subset (N=546) | MTR subset (N=606) | Overall EXPAND populationb (combined MRI) (N=1560) |
|--------------------------------|----------------------------------------|----------------------------------|-------------------|-----------------------------------------------|
|                                | Siponimod (n=656)                      | Placebo (n=351)                  | Siponimod (n=376) | Siponimod (n=388)                           |
|                                |                                        |                                  |                   | Siponimod (n=1037)                         |
|                                |                                        |                                   |                   | Placebo (n=523)                             |
| Age, years, mean (SD)          | 48.0 (7.5)                             | 48.4 (8.0)                       | 47.6 (8.4)       | 48.0 (7.5)                                  |
|                                |                                        |                                   |                   | 48.0 (8.3)                                  |
|                                |                                        |                                   |                   | 47.9 (7.9)                                  |
|                                |                                        |                                   |                   | 48.2 (7.9)                                  |
| Women, n (%)                   | 396 (60.4)                             | 209 (59.5)                       | 231 (61.4)       | 238 (61.3)                                  |
|                                |                                        |                                   |                   | 129 (59.2)                                  |
|                                |                                        |                                   |                   | 631 (60.8)                                  |
|                                |                                        |                                   |                   | 310 (59.3)                                  |
| Duration of MS since first     | 17.1 (8.4)                             | 16.1 (8.5)                       | 16.8 (8.2)       | 16.7 (8.1)                                  |
| symptom, years, mean (SD)      |                                        |                                   |                   | 16.2 (8.7)                                  |
|                                |                                        |                                   |                   | 17.0 (8.3)                                  |
|                                |                                        |                                   |                   | 16.2 (8.3)                                  |
| Time since conversion to       | 3.6 (3.3)                              | 3.2 (3.2)                        | 4.1 (3.9)        | 3.5 (3.3)                                   |
| SPMS, years, mean (SD)         |                                        |                                   |                   | 3.1 (3.2)                                   |
|                                |                                        |                                   |                   | 3.8 (3.5)                                   |
|                                |                                        |                                   |                   | 3.5 (3.2)                                   |
| Baseline EDSS score, margin    | 6.0 (2.5–6.5)                          | 6.0 (2.5–7.0)                    | 6.0 (2.5–7.0)    | 6.0 (2.5–6.5)                               |
| (range)                        |                                        |                                   |                   | 6.0 (2.5–7.0)                               |
| SDMT score, mean (SD)          | 39.5 (13.7)                            | 39.9 (13.6)                      | 37.5 (14.3)      | 39.6 (13.3)                                 |
|                                |                                        |                                   |                   | 40.3 (13.3)                                 |
|                                |                                        |                                   |                   | 38.8 (14.0)                                 |
|                                |                                        |                                   |                   | 39.3 (13.4)                                 |
| Normalized brain volume, cm³,  | 1434.0 (81.2)                          | 1431.9 (86.0)                    | 1403.4 (92.0)    | 1430.3 (80.5)                               |
| mean (SD)                      |                                        |                                   |                   | 1434.1 (89.7)                               |
|                                |                                        |                                   |                   | 1422.7 (86.5)                               |
|                                |                                        |                                   |                   | 1423.5 (87.3)                               |
| Cortical gray matter volume,   | 514.4 (49.4)                           | 511.5 (56.8)                     | 542.3 (56.0)     | 516.2 (47.7)                                |
| cm³, mean (SD)                 |                                        |                                   |                   | 512.9 (55.6)                                |
|                                |                                        |                                   |                   | 524.3 (53.5)                                |
|                                |                                        |                                   |                   | 521.6 (57.3)                                |
| Thalamic volume, cm³, mean (SD)| 13.9 (1.9)                             | 13.9 (1.9)                       | 14.0 (2.1)       | 14.0 (1.8)                                  |
|                                |                                        |                                   |                   | 14.0 (1.9)                                  |
|                                |                                        |                                   |                   | 13.9 (2.0)                                  |
|                                |                                        |                                   |                   | 13.9 (1.9)                                  |
| Patients with ≥ 1 Gd+ T1       | 133 (20.9)                             | 69 (20.2)                        | 94 (25.8)        | 77 (20.4)                                   |
| lesion at baseline, n (%)      |                                        |                                   |                   | 39 (18.6)                                   |
|                                |                                        |                                   |                   | 227 (22.6)                                  |
|                                |                                        |                                   |                   | 107 (21.1)                                  |
| T2 lesion volume, cm³, mean    | 15.1 (16.1)                            | 14.3 (15.9)                      | 16.7 (16.9)      | 14.3 (15.1)                                 |
| (SD)                           |                                        |                                   |                   | 14.2 (15.9)                                 |
|                                |                                        |                                   |                   | 15.7 (16.4)                                 |
|                                |                                        |                                   |                   | 14.7 (15.7)                                 |

EDSS: Expanded Disability Status Scale; FAS: full analysis set; Gd+: gadolinium-enhancing; GM: gray matter; MRI: magnetic resonance imaging; MS: multiple sclerosis; MTR: magnetization transfer ratio; PPS: per-protocol set; SD: standard deviation; SDMT: Symbol Digit Modalities Test; SPMS: secondary progressive multiple sclerosis.

aPPS included all patients from the FAS who did not have any major protocol deviations that could confound interpretation.

bSeven patients from the overall EXPAND population did not have any GM measurement and accordingly are not included in the high-resolution nor in the standard-resolution set.
Percentage changes in brain structure volumes from baseline were analyzed using an MMRM adjusted for visit, treatment, baseline brain volume of a specific region, number of Gd+ T1 lesions at baseline, T2 lesion volume at baseline, treatment-by-visit interaction, and baseline total brain volume-by-visit interaction. aPPS included all patients from the FAS who did not have any major protocol deviations that could confound interpretation.

MTR analyses
In the MTR subset, siponimod was associated with an increase in nMTR from baseline or return to baseline levels in all brain tissues evaluated. These effects were evident at month 24 (PPS).

There were no significant differences in mean nMTR change from baseline to month 12 with siponimod versus placebo in NABT (−0.011 vs −0.014; between-treatment difference: 21%; p = 0.7285), cGM (−0.007 vs −0.009; between-treatment difference: 22%; p = 0.8308), or NAWM (−0.005 vs −0.018; between-treatment difference: 72%; p = 0.1550). However, by month 24, mean nMTR had increased above baseline levels with siponimod, but had continued to decrease in all tissues with placebo (mean nMTR changes for siponimod vs placebo: NABT, 0.001 vs −0.055; between-treatment difference: 102%; p = 0.0050; cGM, 0.008 vs −0.046; between-treatment difference: 117%; p = 0.0141; NAWM, 0.010 vs −0.056; between-treatment difference: 118%; p = 0.0004); the average of the between-treatment differences at months 12 and 24 for NABT, cGM, and NAWM was in the range 85%–105% (Figure 4). The effect of siponimod versus placebo on reduction or suppression of nMTR decrease over time was consistent in the PPS and the FAS (Supplemental Figure S2).

Compared with placebo, siponimod reduced or suppressed nMTR decrease over time across all patient subgroups (baseline age, disease duration, severity, or activity) in both the PPS (Figure 5) and FAS (data not shown), although the differences did not always reach nominal statistical significance. The magnitude of the between-treatment differences varied across subgroups: from 70% to 170% for NABT (Figure 5(a)); from 59% to 188% for cGM (Figure 5(b)); and from 81% to 195% for NAWM (Figure 5(c)).

In newly formed nMTR lesions, siponimod was associated with improved nMTR recovery versus placebo. Total decrease in nMTR from stable pre-lesion to stable post-lesion values was less with siponimod than placebo (−1.35 vs −1.71; between-treatment difference: 0.36; p < 0.0001) (Table 2). This model was based on the latest pre-lesion and latest post-lesion measurements. Similar results were obtained using a multilevel model with all pre-lesion, new lesion, and post-lesion time points included (Figure 6).
Discussion

MRI measures of GM atrophy and brain tissue integrity/myelination provide important insights into changes occurring in brain tissue and may be seen as indicators of chronic, compartmentalized CNS inflammation and neurodegeneration, the primary drivers of progression in patients with SPMS.³⁰ Treatment response on these MRI markers may

---

**Figure 2.** Percentage change in cGM volume (a) from baseline to month 12 and (b) from baseline to month 24 by subgroups according to baseline age, disease duration, severity, or activity* in the combined MRI cohort (PPS*). cGM: cortical gray matter; CI: confidence interval; EDSS: Expanded Disability Status Scale; FAS, full analysis set; Gd+: gadolinium-enhancing; M: month; MRI: magnetic resonance imaging; PPS: per-protocol set; SDMT: Symbol Digit Modalities Test; SPMS: secondary progressive multiple sclerosis.

*Patients were considered to have active SPMS if they had ≥1 relapse in the 2 years before the study and/or had ≥1 Gd+ lesion at baseline; superimposed relapses and Gd+ lesions subgroups are based on events 2 years before or at baseline, respectively.

**PPS included all patients from the FAS who did not have any major protocol deviations that could confound interpretation.**
therefore represent a therapeutic impact on these chronic inflammatory and neurodegenerative pathways. This analysis from EXPAND showed that, compared with placebo, siponimod is associated with slowing of both cortical and thalamic volume loss, improvement in brain tissue integrity/myelination.
Figure 4. Change from baseline to months 12 and 24 in median nMTRa in (a) NABT, (b) cGM, and (c) NAWM in the MTR subset (PPSb).

cGM: cortical gray matter; CI: confidence interval; FAS: full analysis set; M: month; MTR: magnetization transfer ratio; NABT: normal-appearing brain tissue; NAWM: normal-appearing white matter; nMTR: normalized magnetization transfer ratio; PPS: per-protocol set.

aVariations in MTR acquired on different scanners were reduced by MTR normalization, by setting the MTR of high-confidence cGM to 0 and of high-confidence white matter to 1 on the MTR scan of a healthy control individual on the same scanner.

bPPS included all patients from the FAS who did not have any major protocol deviations that could confound interpretation.
Siponimod consistently slowed the progression of cGM atrophy (by 46%–76%) and thalamic atrophy (by 30%–61%) across subgroups stratified by age, disease duration, disease severity (both cognitive and physical), and inflammatory disease activity. A pronounced difference in the dynamics of volume loss was seen between cGM and the thalamus. The presence of gadolinium-enhancing lesions accelerated volume loss in the thalamus but had little impact on cGM atrophy. This observation suggests that different dynamics drive cGM atrophy (less affected by acute inflammatory activity) and thalamic atrophy (substantially affected by acute inflammatory activity).

Subgroups by inflammatory disease activity

| Subgroups                          | Placebo | Siponimod | Between-treatment difference (95% CI) | Percentage reduction vs placebo (p value) |
|------------------------------------|---------|-----------|--------------------------------------|----------------------------------------|
| Age ≤ 45 years                     | 0.128   | -0.030    | 0.021                                | -0.003, 0.007 0.116 (p = 0.002)          |
| Age > 45 years                     | 0.064   | -0.045    | 0.021                                | -0.005, 0.015 0.117 (p = 0.035)          |
| Disease duration ≤ 15 years        | -0.038  | -0.046    | 0.002                                | -0.002, 0.003 0.050 (p = 0.036)          |
| Disease duration > 15 years        | -0.046  | -0.046    | 0.006                                | -0.003, 0.003 0.111 (p = 0.040)          |
| EDSS < 6.0                         | -0.043  | -0.039    | 0.003                                | -0.002, 0.004 0.043 (p = 0.043)          |
| EDSS ≥ 6.0                         | -0.056  | -0.056    | 0.007                                | -0.005, 0.010 0.006 (p = 0.050)          |
| SDMT > 43                          | 0.020   | 0.021     | 0.021                                | -0.002, 0.005 0.116 (p = 0.000)          |
| SDMT ≤ 43                          | 0.019   | 0.013     | 0.013                                | -0.002, 0.004 0.111 (p = 0.003)          |
| Non-active SPMS                    | -0.027  | -0.031    | 0.013                                | -0.002, 0.004 0.111 (p = 0.121)          |
| Active SPMS                        | -0.072  | -0.072    | 0.003                                | -0.001, 0.004 0.040 (p = 0.040)          |
| Without superimposed relapses     | -0.045  | -0.046    | 0.003                                | -0.002, 0.004 0.111 (p = 0.040)          |
| With superimposed relapses        | -0.089  | -0.089    | 0.007                                | -0.001, 0.004 0.043 (p = 0.043)          |
| Without Gd+ lesions                | -0.096  | -0.096    | 0.007                                | -0.001, 0.004 0.043 (p = 0.043)          |
| With Gd+ lesions                   | -0.150  | -0.150    | 0.014                                | -0.001, 0.004 0.043 (p = 0.043)          |
| Percentage reduction vs placebo (p value) | 0.058 (0.002, 0.100) | 0.068 (0.003, 0.104) |
| SDMT > 43                          | 0.019   | 0.019     | 0.019                                | -0.002, 0.004 0.116 (p = 0.000)          |
| SDMT ≤ 43                          | 0.019   | 0.019     | 0.019                                | -0.002, 0.004 0.116 (p = 0.000)          |
| Non-active SPMS                    | -0.027  | -0.031    | 0.013                                | -0.002, 0.004 0.111 (p = 0.040)          |
| Active SPMS                        | -0.072  | -0.072    | 0.003                                | -0.002, 0.004 0.111 (p = 0.040)          |
| Without superimposed relapses     | -0.045  | -0.046    | 0.003                                | -0.002, 0.004 0.111 (p = 0.040)          |
| With superimposed relapses        | -0.089  | -0.089    | 0.007                                | -0.001, 0.004 0.043 (p = 0.043)          |
| Without Gd+ lesions                | -0.096  | -0.096    | 0.007                                | -0.001, 0.004 0.043 (p = 0.043)          |
| With Gd+ lesions                   | -0.150  | -0.150    | 0.014                                | -0.001, 0.004 0.043 (p = 0.043)          |

Figure 5, (Continued)
Nevertheless, the effect of siponimod was consistent in patients with or without inflammatory disease activity (i.e. gadolinium-enhancing lesions). Thus, these findings all together suggest that the action of siponimod is being mediated at least in part) independently of effects on acute inflammation. Reductions in GM atrophy have been associated with positive effects on long-term clinical outcomes, including disability progression and cognitive decline.8–10 The reduced GM atrophy observed here contributes to the previous reported delays in progression of physical disability and cognitive impairment observed with siponimod versus placebo in EXPAND.24,25 Interestingly, other potent anti-inflammatory DMTs such as natalizumab did not show conclusive effects on these measures in patients with SPMS.31 Ocrelizumab reported significant effects on thalamic atrophy but no significant effects in reducing cGM atrophy in patients with progressive MS.32

Siponimod positively affected brain tissue integrity/myelination (assessed by nMTR), consistently slowing nMTR decrease over 24 months in NABT (by 70%–170%), cGM (by 59%–188%), and NAWM (by 81%–195%). This effect was most pronounced in NAWM, in which a significant increase in nMTR became more pronounced over time, with nMTR returning to or surpassing baseline in patients treated with siponimod. Although MTR increases may be associated with resolution of edema, the changes reported here were made in normal-appearing tissues, which are not subject to large changes in water content, and in acute lesions with reference to stable pre-lesion and post-lesion levels. Under these circumstances, the recovery of inflammatory edema associated with acute lesions is not relevant, and these changes could be interpreted as reflecting improvements in myelin density and tissue integrity. This is supported by the fact that nMTR recovered to a greater extent with siponimod than with placebo even in patients without inflammatory disease activity. The fact that the treatment effect on nMTR only became apparent during the second year of treatment suggests that measures of neurodegeneration and

---

### Figure 5

Change in median nMTR from baseline to 24 months in (a) NABT, (b) cGM, and (c) NAWM by subgroups according to baseline age, disease duration, severity, or activity* (PPS). cGM: cortical gray matter; CI: confidence interval; EDSS: Expanded Disability Status Scale; FAS: full analysis set; Gd+: gadolinium-enhancing; M: month; NABT: normal-appearing brain tissue; NAWM: normal-appearing white matter; nMTR: normalized magnetization transfer ratio; PPS: per-protocol set; SDMT: Symbol Digit Modalities Test; SPMS: secondary progressive multiple sclerosis.

- Patients were considered to have active SPMS if they had ≥1 relapse in the 2 years before the study and/or had ≥1 Gd+ lesion at baseline.
- Superimposed relapses and Gd+ lesions subgroups are based on events 2 years before or at baseline, respectively.
- aPPS included all patients from the FAS who did not have any major protocol deviations that could confound interpretation.

#### Table: Absolute change from baseline to M24 in median nMTR in NABT, cGM, and NAWM by subgroups

| Subgroups                     | Median nMTR Reduction (95% CI) | Between-treatment Difference (95% CI) | Percentage Reduction vs Placebo (p value) |
|-------------------------------|-------------------------------|---------------------------------------|------------------------------------------|
| *Age ≤ 45 years*              |                               |                                       |                                          |
| Placebo                       | -0.064                        | 0.015                                 | 112 (p = 0.004)                          |
| Siponimod                     |                                |                                       |                                          |
| *Age > 45 years*              |                               |                                       |                                          |
| Placebo                       | -0.074                        | 0.018                                 | 122 (p = 0.027)                          |
| Siponimod                     |                                |                                       |                                          |
| *Disease duration ≤ 15 years* |                               |                                       |                                          |
| Placebo                       | -0.056                        | 0.009                                 | 115 (p = 0.009)                          |
| Siponimod                     |                                |                                       |                                          |
| *Disease duration > 15 years* |                               |                                       |                                          |
| Placebo                       | -0.061                        | 0.009                                 | 132 (p = 0.049)                          |
| Siponimod                     |                                |                                       |                                          |
| *EDSS < 6.0*                  |                               |                                       |                                          |
| Placebo                       | -0.064                        | 0.026                                 | 140 (p = 0.008)                          |
| Siponimod                     |                                |                                       |                                          |
| *EDSS ≥ 6.0*                  |                               |                                       |                                          |
| Placebo                       | -0.061                        | 0.013                                 | 147 (p = 0.009)                          |
| Siponimod                     |                                |                                       |                                          |
| *SDMT > 43*                   |                               |                                       |                                          |
| Placebo                       | -0.056                        | 0.018                                 | 144 (p = 0.014)                          |
| Siponimod                     |                                |                                       |                                          |
| *SDMT ≤ 43*                   |                               |                                       |                                          |
| Placebo                       | -0.049                        | 0.018                                 | 158 (p = 0.014)                          |
| Siponimod                     |                                |                                       |                                          |
| *Non-active SPMS*             |                               |                                       |                                          |
| Placebo                       | -0.042                        | 0.040                                 | 147 (p = 0.001)                          |
| Siponimod                     |                                |                                       |                                          |
| *Active SPMS*                 |                               |                                       |                                          |
| Placebo                       | -0.070                        | 0.067                                 | 97 (p = 0.001)                           |
| Siponimod                     |                                |                                       |                                          |
| *Without superimposed relapses |                               |                                       |                                          |
| Placebo                       | -0.041                        | 0.068                                 | 166 (p = 0.014)                          |
| Siponimod                     |                                |                                       |                                          |
| *With superimposed relapses*  |                               |                                       |                                          |
| Placebo                       | -0.047                        | 0.060                                 | 81 (p = 0.013)                           |
| Siponimod                     |                                |                                       |                                          |
| *Without Gd+ lesions*         |                               |                                       |                                          |
| Placebo                       | -0.047                        | 0.062                                 | 130 (p = 0.006)                          |
| Siponimod                     |                                |                                       |                                          |
| *With Gd+ lesions*            |                               |                                       |                                          |
| Placebo                       | -0.081                        | 0.095                                 | 117 (p = 0.003)                          |
| Siponimod                     |                                |                                       |                                          |
neuroprotective mechanisms may need to be monitored over a relatively long time before becoming detectable. The fact that siponimod improved nMTR recovery in newly formed nMTR lesions is consistent with observations from preclinical studies showing that siponimod promotes remyelination.22,33

There is little precedence in the clinical trial literature of currently approved DMTs for the observations reported here with siponimod in patients with SPMS. Other DMTs have been reported to slow cortical and thalamic GM atrophy mainly in relapsing MS.32,34 Reports of increased MTR levels have been made in relapsing MS, where dimethyl fumarate has been shown to increase MTR in normal-appearing tissues27 but not in newly formed lesions, and not in SPMS. Observations from preclinical models support a pro-remyelinating effect of siponimod22,33 Taken together with the findings from this study, siponimod may have an impact on the neurodegenerative component of SPMS (in addition to anti-inflammatory effects) that may have contributed to the reduced risk of disability progression and of cognitive worsening observed with siponimod versus placebo in EXPAND. Most DMTs approved for relapsing MS, including highly effective anti-inflammatory drugs such as natalizumab,31 failed to slow disability progression when studied in SPMS or primary progressive multiple sclerosis (PPMS). Conversely, ibudilast, a DMT in development, was associated with benefits on

|                  | Siponimod (N=413, N′=72) | Placebo (N=226, N′=80) | Treatment difference (siponimod vs placebo) | p-value |
|------------------|--------------------------|------------------------|---------------------------------------------|---------|
| nMTR drop (accounting for lesion volume) | −1.35                    | −1.71                  | 0.36                                        | <0.0001 |

FAS: full analysis set; MTR: magnetization transfer ratio; N: number of patients in MTR subset; N′: number of patients with at least one MTR lesion; nMTR: normalized magnetization transfer ratio.

nMTR drop (i.e. nMTR recovery metrics) describes the total decrease in nMTR from pre- to post-nMTR lesion time points. At least three MTR scans were needed: (1) to obtain a stable pre-lesion nMTR value; (2) to detect an acute drop in nMTR indicative of a newly forming lesion; and (3) to obtain a stable post-lesion nMTR value. In this analysis, the latest available measurement before the formation of a new lesion was taken as pre-lesion time point, and the latest available measurement after the formation of a new lesion was taken as the post-lesion time point. Peri-lesion time points were not included.

FAS included all randomized patients with assigned treatments who took at least one dose of study medication.

Figure 6. nMTR recovery metrics in nMTR lesions using a model that included all pre-lesional, new lesion, and post-lesional measurements (FAS4).

FAS: full analysis set; GM: gray matter; MTR: magnetization transfer ratio; nMTR: normalized magnetization transfer ratio; WM: white matter.

nMTR drop (i.e. nMTR recovery metrics) describes the total decrease in nMTR from pre- to post-nMTR lesion time points.

FAS included all randomized patients with assigned treatments who took at least one dose of study medication.
markers of neurodegeneration but not on markers of acute inflammation in a phase 2 trial in patients with progressive MS. Thus, therapeutic action on inflammation and neurodegeneration is de-coupled in other DMTs. As shown in clinical and preclinical studies, siponimod appears to affect both neurodegeneration/demyelination and inflammation, consistent with a dual mode of action.

A few limitations to this study are important to appreciate. Brain volume changes on the order of a fraction of a percent can result from causes other than irreversible neurodegeneration, and the subtle increases in brain volume observed here could reflect increases in the volume of glial cells, and not necessarily neuronal cells (although this may still be an important neuroprotective effect). Similarly, the changes in MTR, although relatively specific for myelin, are associated with changes in other tissue components, which tend to change in a correlated fashion. Changes in tissue water can be associated with small changes in brain volume or MTR simply because of dilution or concentration. However, for this effect to be responsible for the observations reported here, increases in MTR would have to have been associated with increased atrophy, which was not the case. Considering that MRI scans in this study were scheduled annually, it was not possible to determine the exact time of onset of lesion formation for all MTR lesions. This analysis also relied on the assumption that MTR values were stable outside the period of acute lesion formation and recovery.

In summary, these beneficial effects of siponimod on regional brain atrophy and tissue integrity/myelination are consistent with previous preclinical findings and highlight possible direct CNS effects of siponimod, which may be relevant to its effects on disability progression and cognitive processing speed in patients with SPMS.

Acknowledgements
The authors are grateful to Angela Pozo Ramajo (Oxford PharmaGenesis, Oxford, UK) for providing medical writing support, and to Jenny Thorp and Allie Gonzato (Oxford PharmaGenesis) for providing editorial support. These services were sponsored by Novartis Pharma AG (Basel, Switzerland).

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: D.L.A. has received personal fees from Acorda, Albert Charitable Trust, Biogen, Celgene, Frequency Therapeutics, GeNeuro, MedDay, Merck Serono, Novartis, Roche, Sanofi Aventis, and Wave Life Sciences; grants from Biogen, Immunotec, and Novartis; and has equity interest in NeuroRx, outside the submitted work. A. B.-O. has participated as a speaker in meetings sponsored by and received consulting fees and/or grant support from Accure, Atara Biotherapeutics, Biogen, BMS/Celgene/Receptos, GlaxoSmithKline, Gossamer, Janssen/Aceltion, MedImmune, Merck/EMD Serono, Novartis, Roche/GeneTech, and Sanofi Genzyme. R.H.B.B. has received honoraria, speaking, or consulting fees from Biogen, Celgene, EMD Serono, Genentech, MedDay, Novartis, and Roche; research support from Biogen, Genentech, and Novartis; and royalties from Psychological Assessment Resources. B.A.C.C. has received personal compensation for consulting from Alexion, Atara, Autobahn, Avotres, EMD Serono, Novartis, Sanofi, TG Therapeutics, and Therini; and research support from Genentech. G.G. has received compensation for serving as a consultant or speaker for or has received research support from AbbVie, Aslan, Atara Bio, Biogen, BMS-Celgene, GlaxoSmithKline, GW Pharma, Janssen/Aceltion, Japanese Tobacco, Jazz Pharmaceuticals, LilNano, Merck & Co., Merck KGaA/EMD Serono, Novartis, Sanofi Genzyme, Roche/GeneTech, and Teva. R.G. has received compensation for serving as a consultant or speaker from Bayer Healthcare, Biogen Idec, Merck Serono, Novartis, and Teva Neuroscience; and he or the institution he works for has received research support from Bayer Healthcare, Biogen Idec, Merck Serono, Novartis, and Teva Neuroscience; he has also received fees for service as a journal editor from SAGE and Thieme Verlag. P.V. has received fees for service and consulting fees from AB Science, Biogen, Celgene, Imcyse, Merck, Novartis, Roche, Sanofi Genzyme, and Teva, and research support from Novartis, Roche and Sanofi Genzyme. L.K.’s institution (University Hospital Basel) has received steering committee, advisory board and consultancy fees used exclusively for research support in the department, as well as support of educational activities, from Actelion, Allergan, Almirall, Baxalta, Bayer, Biogen, Celgene/Receptos, CSL-Behring, Desitin, Eisai, Excemed, F. Hoffmann-La Roche Ltd., Genzyme, Japan Tobacco, Merck, Minoryx, Novartis, Pfizer, Sanofi Aventis, Santhera, and Teva; and license fees for Neurostatus-UHB products. Research at the MS Center in Basel has been supported by grants from Bayer, Biogen, the European Union, Innosuisse, Novartis, Roche, the Swiss MS Society, and the Swiss National Research Foundation. R.J.F. has received personal fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immune, Novartis, and Teva; grants from Novartis; and other support from Biogen and Novartis (clinical
trial contracts). D.P.-M., S.A., T.H., S.R., and G.K. are the employees of Novartis Pharma AG. F.D. was an employee of Novartis Pharma AG, at the time of writing.

**Funding**
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The EXPAND trial was funded by Novartis Pharma AG (Basel, Switzerland). Novartis Pharma AG supported the development of this manuscript, provided data analyses according to the direction of the authors and paid for medical writing support.

**Supplemental material**
Supplemental material for this article is available online.

**ORCID iDs**
Douglas L Arnold https://orcid.org/0000-0003-4266-0106
Bruce AC Cree https://orcid.org/0000-0001-7689-2533
Ludwig Kappos https://orcid.org/0000-0003-4175-5509
Robert J Fox https://orcid.org/0000-0002-4263-3717

**References**
1. National Multiple Sclerosis Society. Types of MS, https://www.nationalmssociety.org/What-is-MS/Types-of-MS (2020, accessed 6 July 2021).
2. Scalfari A, Neuhaus A, Daumer M, et al. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 2014; 85(1): 67–75.
3. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128(Pt 11): 2705–2712.
4. Larochelle C, Uphaus T, Prat A, et al. Secondary progression in multiple sclerosis: Neuronal exhaustion or distinct pathology? Trends Neurosci 2016; 39: 325–339.
5. Paz Soldán MM, Novotna M, Abou Zeid N, et al. Relapses and disability accumulation in progressive multiple sclerosis. Neurology 2015; 84: 81–88.
6. Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol 2019; 9: 3116.
7. Giorgio A, Battaglini M, Smith SM, et al. Brain atrophy assessment in multiple sclerosis: Importance and limitations. Neuroimaging Clin N Am 2008; 18(4): 675–686.
8. Eijlers AJC, van Geest Q, Dekker I, et al. Predicting cognitive decline in multiple sclerosis: A 5-year follow-up study. Brain 2018; 141: 2605–2618.
9. Eshaghi A, Prados F, Brownlee WJ, et al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol 2018; 83(2): 210–222.
10. Scalfari A, Romualdi C, Nicholas RS, et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. Neurology 2018; 90: e2107–e2118.
11. Brown RA, Narayanan S and Arnold DL. Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis. NeuroImage 2013; 66: 103–109.
12. Chen JT, Collins DL, Atkins HL, et al. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 2008; 63(2): 254–262.
13. Filippi M, Bruck W, Chard D, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2019; 18: 198–210.
14. Mallik S, Samson RS, Wheeler-Kingshott CA, et al. Imaging outcomes for trials of remyelination in multiple sclerosis. J Neurol Neurosurg Psychiatry 2014; 85(12): 1396–1404.
15. Moccia M, van de Pavert S, Eshaghi A, et al. Pathologic correlates of the magnetization transfer ratio in multiple sclerosis. Neurology 2020; 95: e2965–e2976.
16. European Medicines Agency. Mayzent summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_en.pdf (2020, accessed 6 July 2021).
17. Food Drug Administration. Mayzent prescribing information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf (2019, accessed 6 July 2021).
18. Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 2012; 167(5): 1035–1047.
19. Choi JW and Chun J. Lysophospholipids and their receptors in the central nervous system. Biochim Biophys Acta 2013; 1831(1): 20–32.
20. Gentile A, Musella A, Bullitta S, et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. *J Neuroinflammation* 2016; 13: 207.

21. Jaillard C, Harrison S, Stankoff B, et al. Edg8/S1P5: An oligodendroglial receptor with dual function on process retraction and cell survival. *J Neurosci* 2005; 25: 1459–1469.

22. Mannioui A, Vauzanges Q, Fini JB, et al. The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination. *Mult Scler* 2018; 24(11): 1421–1432.

23. O’Sullivan C, Schubart A, Mir AK, et al. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. *J Neuroinflammation* 2016; 13: 31.

24. Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. *Lancet* 2018; 391: 1263–1273.

25. Benedict RHB, Tomic D, Cree BA, et al. Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses. *Neurology* 2021; 96: e376–e386.

26. Inglese M, van Waesberghe JH, Rovaris M, et al. The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. *Neurology* 2003; 60: 853–860.

27. Arnold DL, Gold R, Kappos L, et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. *J Neurol* 2014; 261(12): 2429–2437.

28. Brown JWL, Prados Carrasco F, Eshaghi A, et al. Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. *Mult Scler* 2020; 26(9): 1093–1101.

29. Nakamura K, Guizard N, Fonov VS, et al. Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. *NeuroImage Clin* 2014; 4: 10–17.

30. Correale J, Marrodan M and Ysrraelit MC. Mechanisms of neurodegeneration and axonal dysfunction in progressive multiple sclerosis. *Biomedicines* 2019; 7: 14.

31. Kapoor R, Ho PR, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): A phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. *Lancet Neurol* 2018; 17(5): 405–415.

32. Arnold DL, Sprenger T, Bar-Or A, et al. Effect of ocrelizumab on thalamic atrophy in patients with relapsing and primary progressive multiple sclerosis (1286). *Neurology* 2020; 94: 1286.

33. Martin E, Urban B, Beerli C, et al. Siponimod (BAF312) is a potent promyelinating agent: Preclinical mechanistic observations. *ECTRIMS Online Library* 2019; 278577: P1376.

34. Gaetano L, Haring DA, Radue EW, et al. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis. *Neurology* 2018; 90: e1324–e1332.

35. Naismith RT, Bermel RA, Coffey CS, et al. Effects of ibudilast on MRI measures in the phase 2 SPRINT-MS study. *Neurology* 2021; 96: e491–e500.